Skip to content
lifestyle.lamora.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kalohexis
Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026
June 15, 2026
Kalohexis Announces Publication in Nature Communications Highlighting Dual MC3R/MC4R Activation as a Novel, Durable Mechanism that Drives Weight Loss
June 6, 2026
Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General Obesity
June 6, 2026
Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
April 17, 2026
Kalohexis Appoints Tony Mitchell as Chief Financial Officer
March 31, 2026
Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General Obesity
March 25, 2026
Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases
March 19, 2026